Baseline characteristics by intervention groups*
| Characteristic | Vaccine, 1 × 105 pfu (n = 10) | Vaccine, 5 × 105 pfu (n = 10) | Vaccine, 3 × 106 pfu (n = 10) | All vaccine subjects (n = 30) | Placebo (n = 10) |
|---|---|---|---|---|---|
| Age | |||||
| Mean | 34.5 ± 15.4 | 35.8 ± 12.1 | 36.5 ± 12.8 | 35.6 ± 13.1 | 32.0 ± 9.4 |
| Range | 18–61 | 22–62 | 21–56 | 18–62 | 20–50 |
| Sex, n (%) | |||||
| Male | 3 (30) | 5 (50) | 4 (40) | 12 (40) | 5 (50) |
| Female | 7 (70) | 5 (50) | 6 (60) | 18 (60) | 5 (50) |
| Race,† n (%) | |||||
| Black | 0 | 1 (10) | 1 (10) | 2 (6.7) | 0 |
| White | 9 (90) | 9 (90) | 9 (90) | 27 (90) | 10 (100) |
| Hispanic | 1 (10) | 0 | 0 | 1 (3.3) | 0 |
| Body mass index | 27.8 ± 5.2 | 30.6 ± 7.6 | 28.7 ± 4.6 | 29.0 ± 5.8 | 29.2 ± 6.1 |